# Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

> **NCT03326258** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Estrogen Receptor Negative
- GPNMB Positive
- HER2/Neu Negative
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Progesterone Receptor Negative
- Stage III Breast Cancer AJCC v7
- Stage III Cutaneous Melanoma AJCC v7
- Stage III Uveal Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Uveal Melanoma AJCC v7
- Triple-Negative Breast Carcinoma
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Glembatumumab Vedotin
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03326258
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-20
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-04-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study itself was Disapproved on 04/20/2018 and will not be moving forward.
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326258, "Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03326258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*